1 Title: Transient increased risk of influenza infection following RSV infection in South Africa;

- 3
- 4 Authors: Naomi R Waterlow¹, Jackie Kleynhans^{2,3}, Nicole Wolter^{2,4}, Stefano Tempia^{2,3}, Rosalind M
- 5 Eggo¹, Orienka Hellferscee^{2,4}, Limakatso Lebina^{5,6}, Neil Martinson^{5,7}, Ryan G Wagner^{2,8}, Jocelyn Moyes²,
- 6 Anne von Gottberg^{2,4}, Cheryl Cohen^{2,3}, Stefan Flasche¹
- 7
- 8 ¹ Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical
- 9 Medicine, London, UK
- ² Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases,
- 11 Johnanesburg, South Africa
- ³ School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
- 13 South Africa
- ⁴ School of Pathology, Faculty of Medicine, University of the Witewatersand, Johannesburg, South Africa
- ⁵ Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
- ⁶ Africa Health Research Institute, Durban, South Africa
- 17 ⁷John Hopkins University Center for TB Research, Baltimore MD
- 18 ⁸ South African Medical Research Council/Rural Public Health and Health Transitions Research Unit
- 19 (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
- 20 Johannesburg, South Africa
- 21
- 22 I These authors contributed equally
- 23
- 24
- 25 26
- 20
- 27
- 28 Research in Context

² findings from the PHIRST study, South Africa, 2016-2018.

We searched PubMed titles and abstracts for the terms "influenza", "RSV" or "Respiratory

0	\sim
•)	u
~	J

30 Evidence before this study

31

33	syncytial virus" and "interaction", "competition" or "enhancement" resulting in 56 articles,
34	excluding reviews. Evidence for the potential interaction of influenza and RSV originates
35	from analyses of viral surveillance and experimental non-human studies, or isolated
36	mathematical models. Most such studies suggest potential competitive exclusion of RSV
37	and Influenza but are prone to potential confounding and unable to test the links between
38	biological mechanisms and population level impacts.
39	
40	Added value of this study
41	
42	This longitudinal study with frequent testing of participants for colonisation with RSV and
43	Influenza allows sufficient resolution to analyse direct evidence for interaction of both viruses
44	on colonisation. In contrast to evidence insofar we find that the effect of RSV colonisation on
45	the risk for influenza acquisition is short lived and synergistic, but unlikely to substantially
46	effect influenza epidemiology on population level.
47	
48	Implications of all the available evidence
49	
50	RSV infections are likely to have limited impact on influenza circulation.
51	
52	
53	
54	
55	
56	Abstract:

57

- 58 Large-scale prevention of respiratory syncytial virus (RSV) infection may have ecological 59 consequences for co-circulating pathogens, including influenza. We assessed if and for how 60 long RSV infection alters the risk for subsequent influenza infection. 61 62 We analysed a prospective longitudinal cohort study conducted in South Africa between 63 2016 and 2018. For participating households, nasopharyngeal samples were taken twice 64 weekly, irrespective of symptoms, across three respiratory virus seasons, and real-time 65 polymerase chain reaction (PCR) was used to identify infection with RSV and/or influenza. 66 We fitted an individual-level hidden markov transmission model in order to estimate RSV and 67 influenza infection rates and their interdependence. 68 69 Of a total of 122113 samples collected, 1265 (1.0%) were positive for influenza and 1002 70 (0.8%) positive for RSV, with 15 (0.01%) samples from 12 individuals positive for both 71 influenza and RSV. We observed 2.25-fold higher incidence of co-infection than expected if 72 assuming infections were unrelated. We estimated that infection with influenza is 2.13 (95% 73 CI 0.97 - 4.69) times more likely when already infected with, and for a week following, RSV 74 infection, adjusted for age. This equates to 1.4% of influenza infections that may be 75 attributable to RSV in this population. Due to the local seasonality (RSV season precedes 76 the influenza season), we were unable to estimate changes in RSV infection risk following 77 influenza infection.
 - 78

RSV infection was associated with an increased risk for influenza infection for a short period
after infection. However, the impact on population-level transmission dynamics of this
individual-level synergistic effect was not measurable in this setting.

- 82
- 83

84 Background

85

86	Globally, in 2019 there were an estimated 17.2 billion upper respiratory tract infections (1),
87	which is a common presentation of the over 200 known respiratory virus strains that cause
88	illness in humans(1). These viruses may interact, resulting in cross-protective or enhancing
89	effects for transmission and/or disease severity(2-5), and can result in unintended knock-on
90	effects from public health interventions. However, other factors, including a change in
91	behaviour relevant to transmission, may also underlie apparent pathogen interaction. An
92	example of ecological knock-on effects that were not caused by pathogen interaction but by
93	a change in social behaviour has been observed as a result of social distancing to mitigate
94	the Coronavirus Disease 2019 (COVID-19) pandemic(6). Vaccination may increase the
95	burden of an untargeted virus if an infection with the targeted pathogen is cross-protective,
96	or reduce the prevalence of enhancing pathogens. Understanding these potential ecological
97	knock-on effects is particularly important for pathogens where vaccines are in late-stage
98	clinical development, such as for respiratory syncytial virus (RSV) where successful Phase
99	III trials have recently been reported for multiple vaccines(7,8).

100

101 While RSV may be a critical factor underlying a substantial part of severe pneumococcal 102 infections(9), some evidence has suggested a competition for a similar ecological niche with 103 influenza viruses(5). However, much of the available evidence is based on in vitro 104 experiments or population-level ecological studies that identify the correlation of respective 105 case series; e.g. following the 2009 influenza pandemic, many studies showed a delayed or 106 absent RSV epidemic(10-14), however, this was not uniformly the case(15). Surveillance in 107 non-pandemic years has shown that the epidemic incidence peaks of influenza and RSV 108 rarely coincide in geographies where influenza and RSV circulate at the same time of year 109 (16,17). Immunological evidence from studies such as cell culture and mouse models 110 suggest potential inhibition of heterologous growth(18–21), but the extent that such 111 interactions impact transmission among humans is unclear.

113 A key issue faced by many epidemiological studies of RSV and influenza interaction is that 114 they rely on syndromic surveillance of medically attended illness for their inference, even 115 though asymptomatic infections and non-medically attended illness are likely important 116 drivers of transmission and interaction. We analyse a unique longitudinal household study 117 with frequent asymptomatic sampling to help better understand the interdependence of RSV 118 and influenza infection. 119 120 121 Methods 122 123 Study population and data collection 124 125 Influenza and RSV infections were identified as part of the Prospective Household cohort 126 study of influenza, respiratory syncytial virus and other respiratory pathogens community 127 burden and Transmission dynamics in South Africa (PHIRST) described in detail elsewhere 128 (22). The study was conducted between 2016 and 2018 in both a rural and an urban 129 community in South Africa. Households of more than two individuals were enrolled if 80% or 130 more individuals from the household provided consent. The study was conducted over three 131 respiratory virus seasons, with new households enrolled each year for a follow-up period of 132 ten months, except in the 2016 season, where only 6 months of follow-up occurred, starting 133 in the middle of the RSV season (Figure 1). Nasopharyngeal swabs were collected twice per 134 week, irrespective of symptoms, and samples were subsequently analysed by real-time 135 polymerase chain reaction (PCR) for the presence of RSV and influenza viruses. 136 137 We defined an 'episode' as one or more positive samples that do not have more than 14 138 days of negative samples between them (23,24). We define 'dual infection' as being infected

139 with both viruses at the same time (i.e. the same sample is positive for both RSV and

influenza). We defined 'overlapping episodes' as when an RSV episode coincided at somepoint in time with an influenza episode.

142

143 Crude Analyses

144

145 For the crude analysis, we included only the first positive sample for each episode, so as not 146 to double-count infections. For each individual with an RSV infection (i.e. episode) in the 147 dataset, we identified all controls who were tested but uninfected on the same day and were 148 in the same age group (defined as ages <5, 5 to 18, 19-65 and >65 years). We then 149 calculated the number of individuals among cases (exposed) and controls (unexposed) that 150 had a positive sample for influenza infection (outcome variable) on the day of the first 151 positive RSV sample or up to 21 days before or after. This range was used as we consider it 152 a biologically plausible range for interaction. We repeated this process in reverse, identifying 153 RSV-positive samples on the same and nearby days as an influenza episode started. Risk 154 ratios and the respective confidence intervals were then calculated across weekly 155 aggregated counts (see supplement). 156

157 Secondly, we compared the observed frequency of samples indicating RSV and influenza 158 co-infection versus the expected frequency of co-infection if assuming that the risk of RSV 159 and influenza infection were uncorrelated. The expected proportion of co-infections on a 160 given day is calculated by multiplying the prevalence of RSV and influenza infections on that 161 day. The expected proportion of co-infections overall is then the sum of expected co-162 infection frequency on the sampling days (proportion times the number of samples) divided 163 by the total number of samples taken during the study. We compared the expected 164 proportion of co-infected samples against the observed proportion of co-infected samples 165 using a two-proportion z-test. All analysis was conducted in R.

166

167 Model

168

169	We used a multi-state Markov modelling framework to model the transition between RSV,
170	influenza and co-infection states (25). Each individual is classed as either Susceptible (S),
171	Infectious (I), Period of interaction following infectiousness (P) or Recovered (R) (Figure 2).
172	We fit parameters for the time-dependent Force of Infection (FOI) of both viruses and the
173	strength of interaction for each virus. The time dependence of the FOI aims to account for
174	the timing of the relative RSV and influenza seasons, assuming this may be related to some
175	unmeasured factors. Interaction can occur during, and for one week after infection, as this
176	was the scale of time indicated in previous studies (26). We also ran sensitivity analyses with
177	2, 3 and 4 weeks, respectively. The interaction can be competitive (<1 indicating that
178	infection with one partially mitigates acquisition of the other) or synergistic (>1 indicating that
179	infection with one enhances the probability of acquisition with the other pathogen), and we
180	test the null hypothesis of there being no interaction. Other parameters were informed from
181	literature estimates (Table 1). The FOI is time-dependent, independently estimated every 30-
182	day time window, and age group is included as a covariate (<5 years, 5 -18 years, 19-65
183	years, 65 years or older). Further details are given in the supplement.
184	
185	We assumed that all individuals were susceptible to both RSV and influenza infection at
186	recruitment ($S_{RSV}S_{INF}$ class in the model), and that each individual could only be infected by
187	each virus once during a season. If a further infection occurred, data on the individual was
188	removed from the time point of the re-infection. We assumed that positive tests of the same
189	virus occurring within a 14-day time window were related to the same infection(27).
190	
191	The observation of a current RSV or influenza infection in the study did not allow us to
192	distinguish the period of post-infection interaction from the subsequent state of immunity
193	without interaction, so in the model, these were included as "censored" states. This means

194 the model estimates which of these states each individual is in at a given time.

196	In addition, we assumed that all RSV and influenza positive tests were true positives, while
197	we estimated the proportion of false negative tests in the model framework. We did this by
198	allowing misclassification of states for negative samples.
199	

- 200 The model was implemented and fit using the R *msm* package(25), with the quasi-Newton
- 201 method "BFGS", which builds up a picture of the surface to be optimised using function
- values and gradients. We ran the model twice, with different initial values each time.

203

204 Sensitivity Analysis

- 205 We tested the sensitivity of our results to alternative assumptions of the duration of
- 206 interaction, rerunning the model where interaction can occur during infection and for the
- following 2 weeks, the following 3 weeks and the following 4 weeks. We also attempted to
- run the model with shorter time intervals for the FOI, as well as excluding the first season
- 209 (2016) where most of the co-infections occurred, however neither of these models reached
- 210 convergence.
- 211 All analysis was conducted in R. Code and summarised data are available here
- 212 <u>https://github.com/NaomiWaterlow/markov_model.</u>

213 Results

214 Out of a total number of 122113 individual-days swab collection was set to occur (across 215 1684 individuals), 13% of results were missing from the analysis, either due to unavailability 216 of the individuals or processing errors (such as incorrect labelling or leakage). In total, there 217 were 1265 positive influenza samples and 1002 positive RSV samples, with a median of 71 218 samples taken per individual (95% quantiles 25-81) over the study period. These clustered 219 into 574 and 488 episodes of infection with influenza or RSV, of which 14% (83/574) and 8% 220 (40/488), respectively, were episodes of reinfection of an individual with the same pathogen 221 within a season (Figure 1 A&C). There were 15 dual infection samples across 12 episodes of

infection, in 12 individuals: two in children <5 years old, nine in children 5-18 years old and

223 one in an adult 19-65 years old. There were 18 samples that were classified as overlapping,

- corresponding to the same 12 infections and individuals as the dual infections, with no
- further overlapping episodes that were not detected as a dual infection.
- 226 The RSV epidemics occurred from February to June, with peak incidence around March,
- 227 whilst the influenza epidemic occurred later in the year between May and October, typically
- 228 peaking in September (Figure 1D). The mean duration of episodes (from first to last positive
- samples) was 6.8 days for RSV (95% CI 6.1 7.4 days) and 6.5 days for influenza (95% CI
- 230 6.0 7.0 days). The infection attack rate for each season was 34% (216/512), 41%

231 (216/577) and 42% (216/565) for influenza and 24% (131/542), 32% (184/577) and 38%

- 232 (216/565) for RSV, although data collection over the first season was for a shorter period,
- 233 missing much of the RSV season. The median age of infected individuals for influenza and
- RSV in the first season was 10 and 7 years, respectively (ranges 0-79 and 0-70), compared

to 15 and 19 years in the second season (ranges 0-91 and 0-91) and 8 and 11 years in the

third season (ranges 0-70 and 0-91) (Figure 1B).



Figure 1: A) All positive test results over time for influenza (Flu) and Respiratory Syncytial

- 239 Virus (RSV). B) Number of infection episodes in each age group, across the three seasons
- C) Number of individuals against the number of infections for each virus, where positive tests within 14 days are assumed to be due to the same infection. D) Seasonality of influenza and
- within 14 days are assumed to be due to the same infection. D) Seasonality of influenza and
 RSV infections, depicting the percentage of annual positive tests by month of the year. The
- semi-transparent lines depict the individual seasons. The solid lines depict the mean across
- seasons. Dark shaded areas depict months where no samples were taken, and the light
- shaded area shows samples not taken in the 2016 season.
- 246 In the crude analysis, a small increase in the risk ratio for influenza infection was observed
- the week following a positive RSV sample (1.99, 95%CI 0.96 4.11) (Figure 2A), although
- 248 confidence intervals crossed one. Whilst there was also an increased risk ratio for RSV
- 249 infection in the week following influenza infection, this was of a smaller magnitude and had
- 250 lower confidence (1.37 95%Cl 0.64 2.95).
- Assuming independence of RSV and influenza infection, we would expect 6.67 co-infected
- samples to occur during the study period, compared to 15 that were observed; a 2.25 times
- 253 higher rate of co-infections albeit not statistically significant (95%CI 0.73 3.77, p-value
- 254 0.12). All but one of the actual co-infections occurred in the first season (Figure 2B).



Figure 2: A) Analysis 1. Risk ratio of the risk of being infected by the second virus (outcome),
when exposed to the primary virus. Points indicated the estimate and error bars the 95%
confidence interval. The dashed line indicates a risk ratio of 0, equating to no effect. B)
Analysis 2. Expected versus observed dual infections per week.

As the RSV season preceded the influenza season, only 15 /1684 (0.9%) study participants

were infected with influenza and a subsequent RSV infection in the same season. Thus, in

the Markov model, the estimated strength of interaction exerted by infection of influenza on

264 RSV infection probability had wide confidence intervals, which crossed 1 (the Null

265 hypothesis indicating no effect): RSV infection was 0.93 (95% CI: 0.2 - 4.3) times as likely in

the presence of influenza infection compared to without influenza infection.

267 Conversely, 158/1684 (9.4%) individuals were infected with RSV and, subsequently,

268 influenza. We estimated a synergistic interaction effect of RSV infection on the risk for

- 269 influenza infection: infection with influenza was 2.13 (95% CI: 0.97 4.69) times more likely
- 270 for one week following the first positive sample of an RSV infection episode. This translates
- to a very small population-level effect: of the 574 observed influenza episodes, only 12 were
- 272 overlapping infections. If we add to these the infections that occurred within 7 days of testing

273 negative after an infection episode with the other virus, we get a total of 18 extended overlap

- 274 episodes. Eight of these 18 overlapping episodes would have been avoided without the
- synergistic effect, resulting in a reduction in total influenza cases in this cohort of 1.4%.
- 276 The model further estimated that the sensitivity of testing for influenza and RSV was very
- high, with a false negative rate of 0.75% (95% CI: 0.72 0.77). For RSV, those <5 years had
- the highest risk of being infected, followed by individuals aged 5-18 years (hazard ratio 0.51
- 279 (95% CI: 0.41- 0.63)), 19-65 years (hazard ratio 0.29 (95% CI: 0.23- 0.37)) and 65 years and
- older (hazard ratio 0.13 (95% CI: 0.06- 0.30)) (Figure 3B). A similar but smaller reduction in
- 281 infection risk with increasing age was observed for influenza (Figure 4).
- 282 Our results on the strength of the synergistic effect of RSV infection on the risk for influenza
- 283 infection were robust to alternative assumptions on the duration of said effect. We estimated
- 284 that influenza infection is 1.76 (95%CI 0.88 3.54) times, 1.72 (95%CI 0.92 3.19) times and
- 285 1.78 (1.02 3.09) times more likely following an RSV infection if we assumed that the
- interaction lasted for 2, 3 or 4 weeks respectively (See supplement).
- 287 Our sensitivity analyses with a shorter time interval for the changing FOI, and for the default
- 288 model but excluding the first season of data did not converge.



289

290 Figure 3: A) Model diagram. Shaded red compartments are censored states. B) Age group hazard ratios of infection by age on a log scale,

291 compared to the <5 years as the base age group. C) Interaction multiplier for each virus, for the main analysis (7 days interaction), and the

292 duration sensitivity analysis. An interaction multiplier of x indicates that Transmission from S to I with the other virus is x times more likely when

already infected with the initial virus. D) Force infection over time for influenza and RSV (7-day interaction model). Lines indicate the mean

294 value, and the shaded ribbons the 95% Cl.

295 Discussion

296 We found over twice as many co-infections than expected, if assuming no interaction, and 297 similarly estimate in the model that influenza infection risk is 2.13 (95% CI: 0.97 - 4.69) 298 higher during or shortly after RSV infection. This, however, translates to a very small 299 population-level impact. Whilst we did not find evidence to suggest elevated RSV infection 300 risk following influenza infection, this may have been due to the small sample size of RSV 301 infections subsequent to influenza. Since the observed synergy in infection risk was 302 estimated to be short-lived, ecological consequences on influenza infection risk following 303 widespread RSV prevention are unlikely; however, they may be amplified by increases in 304 severity as a result of co-infection(2), which we did not address in this paper. 305 The major strength of this analysis is that the data consist of regular symptom-agnostic 306 swabbing of study participants, allowing the inclusion of mild and asymptomatic infections 307 (which can be a large proportion), rather than just symptomatic and severe cases. This high-308 quality data results in major benefits. Firstly, changes in infection risk may be obscured by 309 the impacts of dual infection on clinical severity when using syndromic surveillance data, 310 resulting in higher reporting. This has been avoided in our study. The current literature gives 311 mixed results on the increased severity of dual infections, with some studies estimating an 312 increased severity of dual infections (26,28), and others not finding evidence of a significant 313 effect (29,30). The impact of RSV and influenza co-infection on the severity of infection was 314 outside the scope of this study.

A second benefit of symptom-agnostic swabbing is that no bias is introduced as a result of the inherent difference between those with symptoms and those without. For instance, it could be that those with more severe symptoms may have weaker immune systems than those with milder symptoms, and therefore may also be more susceptible to infection with both viruses. Including all infections in the analysis removes this potential bias.

Thirdly, by fitting models to infections rather than clinical cases, we reduce the number of parameters required to be fitted, as we do not need to include reporting rate parameters. Fitting complex interaction models is difficult, and it is not possible to differentiate extreme interaction parameter values from less extreme ones(31).

324 A further strength of the data used in this model is its longitudinal nature. We used data 325 across almost 3 seasons, where the same individuals were sampled within (but not across) 326 each season, giving us detailed infection data. There may, however, be bias introduced due 327 to missing data, with 13% of swabs missing. Whilst the majority of these are likely due to 328 unbiased reasons (such as travel and holidays), other potential reasons, such as severe 329 infections resulting in hospitalisations, may have resulted in bias. However, due to the 330 regularity of the swabbing, any bias introduced due to these reasons would have been 331 minimal, as infection would likely have been identified on a neighbouring swab date (as the 332 median recorded episode duration was 6 and 5.5 days for RSV and influenza, respectively) 333 and very few hospitalisations were found in the cohorts overall. In addition, the hidden 334 Markov model inference takes into account missing data.

335 Our model results differ from some previous evidence of interaction between RSV and 336 influenza. However, these earlier findings are not based on mechanistic models and could 337 therefore be confounded by other transmission-relevant factors, such as contact rates. This 338 is likely the case with studies investigating causality for the shifts in RSV patterns following 339 the 2009 influenza pandemic (10,12–14), where, despite no governmentally imposed social 340 restrictions, fear of the virus could have altered contact behaviours (32). In our previous work 341 on evidence for interaction between the two viruses in Nha Trang, Vietnam, we showed that 342 the data was compatible with either a ~41% reduction in susceptibility for 10 days following 343 infection with the other virus, or no reduction in susceptibility following infection (26). This is 344 not incompatible with our current estimate of a small increase in susceptibility on the 345 individual level, which would likely not have an impact on the population scale. Our previous 346 model used population-level symptomatic surveillance data, and we did not account for the

possibility of cross-protective interaction, as opposed to this study, where the individual-leveldata allowed us to explore a broader parameter space.

Age-related susceptibility to infection reduction is generally considered to be the case for
RSV, whether this be due to age directly, or due to subsequent infections. For instance,
Henderson et al. showed that attack rates during an epidemic were 98% for the 1st infection,
75% for a second infection and 65% for a third infection (33). As increasing numbers of
previous infections will strongly correlate with age, this is not out of line with our estimates of
age-related hazard rates.

Whilst the evidence we provide shows an increased likelihood of influenza infection following RSV, this is of very small magnitude, most likely resulting in little measurable impact from co-infection at the population level. Of relevance to the implementation of public health policies, a reduction in RSV circulation, for example, due to vaccination, is therefore unlikely to result in substantial replacement with influenza. This provides evidence against a potential concern for the implementation of an RSV vaccine.

361 Our model was limited by the need to reduce complexity, and we, therefore, did not allow for 362 waning of immunity, and hence we were unable to include repeat infection of the same virus 363 within a season, or any serological data. Repeat infections of influenza and RSV are likely 364 due to different subtypes. However, as our estimate of interaction is very short-lived, not 365 including these repeat infections are unlikely to have affected our estimates. We were 366 additionally limited by the lack of RSV cases following influenza infections, meaning we had 367 very large confidence on the estimates of the effect of influenza on RSV. We also took a 368 simplistic approach of homogenous population mixing. An alternative explanation of the 369 elevated rate of co-infections is that behavioural aspects may have influenced both the 370 probability of getting RSV and influenza. This could be, for instance, attendance at a 371 crowded event (e.g. religious ceremony) resulting in an increased chance of infection with 372 both viruses. Alternatively, it may just be individuals with higher contacts due to factors such

373	as their employment type.	Ideally, we would be able	to quantify times o	f exposure to the
-----	---------------------------	---------------------------	---------------------	-------------------

- 374 viruses, for example, through infections in the household, however, we did not have
- 375 sufficient data to analyse this in the current study. We also did not look at climatic factors
- 376 specifically, instead assuming they were captured by our time-varying FOI. This time-varying
- 377 FOI also allowed us to account for the fact that the influenza season follows the RSV
- 378 season. We also note that all but one overlapping episode for RSV and influenza were
- 379 collected during the first season. This is likely due to differing subtypes or age factors, which
- 380 we were not able to include in our crude analysis of expected dual infections. We attempted
- 381 to run a sensitivity analysis excluding the first season of data where the majority of co-
- infections were detected, however this model did not converge, likely due to small numbers.
- 383 Overall, the use of a mathematical model combined with a highly detailed longitudinal
- 384 population-based infection study allowed us to estimate the interaction of RSV and influenza
- in South Africa. Our findings suggest that concerns for increased influenza circulation as a
- 386 result of the introduction of RSV prevention strategies may not materialise.
- 387

388 References

- Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. eClinicalMedicine
 Internetic 2021, kel 4 feited 2022 May 4127. Available from:
- 391 [Internet]. 2021 Jul 1 [cited 2022 May 4];37. Available from:
- 392 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00266-2/fulltext
- Waterlow NR, Toizumi M, Leeuwen E van, Nguyen HAT, Myint-Yoshida L, Eggo RM, et
 al. Evidence for influenza and RSV interaction from 10 years of enhanced surveillance in
 Nha Trang, Vietnam, a modelling study. PLOS Comput Biol. 2022 Jun
 24;18(6):e1010234.
- Velasco-Hernández JX, Núñez-López M, Comas-García A, Cherpitel DEN, Ocampo MC.
 Superinfection between Influenza and RSV alternating patterns in San Luis Potosí State,
 México. PLoS ONE [Internet]. 2015;10(3). Available from:
- 400 http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4372574&blobtype=pdf
- 401 4. Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and Bacterial
 402 Interactions in the Upper Respiratory Tract. Available from:
- 403 http://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1003057&type
 404 =printable
- 405 5. Opatowski L, Baguelin M, Eggo RM. REVIEW Influenza Interaction with Cocirculating
 406 Pathogens, and Its Impact on Surveillance, Pathogenesis and Epidemic Profile: A Key

407 408		Role for Mathematical Modeling. Hobman TC, editor. PLOS Pathog. 2017 Feb:14(2):e1006770–e1006770
409	6	Kim MC, Kweon QJ, Lim YK, Choi SH, Chung JW, Lee MK, Impact of social distancing
410	0.	on the spread of common respiratory viruses during the coronavirus disease outbreak.
411		PLOS ONE. 2021 Jun 14:16(6):e0252963.
412	7.	GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1%
413	••	reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
414		GSK [Internet]. [cited 2023 Jan 16]. Available from: https://www.gsk.com/en-
415		gb/media/press-releases/gsk-s-older-adult-respiratory-syncytial-virus-rsv-vaccine-
416		candidate/
417	8.	Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial
418		for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate Pfizer [Internet].
419		[cited 2023 Jan 16]. Available from: https://www.pfizer.com/news/press-release/press-
420		release-detail/pfizer-announces-positive-top-line-data-phase-3-global
421	9.	Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between
422		Respiratory Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series
423		Analysis of US Hospitalization Data. PLOS Med. 2015 Jan 6;12(1):e1001776.
424	10.	Meningher T, Hindiyeh M, Regev L, Sherbany H, Mendelson E, Mandelboim M.
425		Relationships between A(H1N1)pdm09 influenza infection and infections with other
426		respiratory viruses. Influenza Other Respir Viruses. 2014 Jul;8(4):422–30.
427	11.	Hirsh S, Hindiyeh M, Kolet L, Regev L, Sherbany H, Yaary K, et al. Epidemiological
428		changes of Respiratory Syncytial Virus (RSV) infections in Israel. PLoS ONE [Internet].
429		2014;9(3). Available from:
430		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940902/pdf/pone.0090515.pdf
431	12.	Casalegno JS, Ottmann M, Bouscambert-Duchamp M, Valette M, Morfin F, Lina B.
432		Impact of the 2009 influenza a(H1N1) pandemic wave on the pattern of hibernal
433	4.0	respiratory virus epidemics, France, 2009. Eurosurveillance. 2010 Feb;15(6):2–2.
434	13.	Grondahl B, Ankermann T, Von Bismarck P, Rockahr S, Kowalzik F, Gehring S, et al.
435		The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of
430		other viral pathogens causing acute respiratory tract infections in children. Infection.
437	11	2014;42(2):303-6.
430	14.	an the circulation of reconstructory viruses 2000 2011 Influenza Other Reconstructory 2009
439 440		May:6(3):e6-10
441	15.	Navarro-Marí JM. Pérez-Ruiz M. Galán Montemavor JC. Marcos Maeso MÁ. Reina J. de
442		Oña Navarro M. et al. Circulation of other respiratory viruses and viral co-infection during
443		the 2009 pandemic influenza. Enfermedades Infecc Microbiol Clínica. 2012 Oct;30:25–
444		31.
445	16.	Glezen WP, Paredes A, Taber LH. Influenza in Children. JAMA. 1980
446		Apr;243(13):1345–1345.
447	17.	Anestad G, Nordbo SA. Interference between outbreaks of respiratory viruses. Euro
448		Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2009 Oct;14(41):19359–19359.
449	18.	Shinjoh M, Omoe K, Saito N, Matsuo N, Nerome K. In vitro growth profiles of respiratory
450		syncytial virus in the presence of influenza virus. Acta Virol. 2000 Apr;44(2):91-7.
451	19.	Lee YJ, Lee JY, Jang YH, Seo SU, Chang J, Seong BL. Non-specific Effect of Vaccines:
452		Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated
453		Influenza Vaccine. Front Microbiol. 2018 Jan;9:83–83.
454	20.	Walzl G, Tafuro S, Moss P, Openshaw PJ, Hussell T. Influenza virus lung infection

455		protects from respiratory syncytial virus-induced immunopathology. J Exp Med. 2000
456	~	Nov;192(9):1317–26.
457	21.	Hamilton J. Club cells surviving influenza A virus infection induce temporary nonspecific
458	22	antiviral immunity.
459	ZZ.	Conen C, Kleynnans J, Moyes J, McMorrow ML, Treumicht FK, Heillerscee O, et al.
460		Asymptomatic transmission and high community burden of seasonal initialization and a
401		dipan and a fural community in South Africa, 2017–18 (PHIRST): a population conort
402	22	Maghadami M. A Narrativa Paviaw of Influenza: A Seasonal and Pandomic Disease
403	23.	Iran I Med Sci 2017 Jan:42(1):2–13
465	24	Filand I.S. Respiratory Syncytial Virus: Diagnosis Treatment and Prevention . I Pediatr
466	21.	Pharmacol Ther JPPT 2009:14(2):75–85
467	25	Jackson C. Multi-State Models for Panel Data: The msm Package for R. J. Stat Softw
468	20.	2011 Jan 4:38:1–28.
469	26.	Waterlow NR, Toizumi M, Leeuwen E van, Nguyen HAT, Myint-Yoshida L, Eggo RM, et
470		al. Evidence for Influenza and RSV interaction from 10 years of enhanced surveillance in
471		Nha Trang, Vietnam, a modelling study [Internet]. 2021 Oct [cited 2021 Dec 17] p.
472		2021.10.19.21265189. Available from:
473		https://www.medrxiv.org/content/10.1101/2021.10.19.21265189v1
474	27.	Okiro EA, White LJ, Ngama M, Cane PA, Medley GF, Nokes DJ. Duration of shedding of
475		respiratory syncytial virus in a community study of Kenyan children. BMC Infect Dis.
476		2010 Dec;10(1):15–15.
477	28.	George JA, AlShamsi SH, Alhammadi MH, Alsuwaidi AR. Exacerbation of Influenza A
478		Virus Disease Severity by Respiratory Syncytial Virus Co-Infection in a Mouse Model.
479		Viruses. 2021 Aug 18;13(8):1630.
480	29.	De Paulis M, Gilio AE, Ferraro AA, Ferronato AE, do Sacramento PR, Botosso VF, et al.
481		Severity of viral confection in hospitalized infants with respiratory syncytial virus
482	20	Infection. J Pediatr (Rio J). 2011;87(4):307–13.
483	30.	Asher SA, Science ME, Tran D, Smieja M, Mergien A, Meriz D, et al. Clinical Disease
404 185		Review and Meta-Analysis Available from:
486		http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4059637&blobtype=pdf
487	31	Waterlow NR Elasche S Minter A Eggo RM Competition between RSV and influenza:
488	0	limits of modelling inference from surveillance data. Epidemics. 2021 Mar 26:100460.
489	32.	Rubin GJ. Amlôt R. Page L. Wesselv S. Public perceptions, anxiety, and behaviour
490		change in relation to the swine flu outbreak: cross sectional telephone survey. BMJ.
491		2009 Jul 2;339:b2651.
492	33.	Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory-Syncytial-Virus
493		Infections, Reinfections and Immunity. N Engl J Med. 1979 Mar;300(10):530-4.
494		
495		
496		
497	Dee	claration of Interests: No conflicts of interest.
498	_	••••••••••••••••••••••••••••••••••••••
499	Fu	nding acknowledgment: The study was funded through a cooperative agreement with
500	the	United States Centers for Disease Control and Prevention (CDC) (grant number
501	100	JTIPUUTU48). Testing for KSV was supported by the Bill and Melinda Gates Foundation

- 502 (Grant number: OPP1164778). The data analyses were supported by Germany's Innovation
- 503 Fund of the Joint Federal Committee (grant no. 01VSF18015).